4SC AG Annual cash flow by MarketWatch. View VSC net cash flow, operating cash flow, operating expenses and cash dividends.
Reuters: 4SC holds cash balance/funds of 43,353 thousand euros as of Sept. 30
4SC holds cash balance/funds of 43,353 thousand euros as of Sept. 30
4SC AG: Capital reduction to zero and simultaneous capital increase effective – Delisting from the Frankfurt Stock Exchange Planegg-Martinsried, Germany, 16 December 2025 – 4SC AG announces that the capital reduction to zero euros and the simultaneous cash capital increase of approximately €2.7 million, which were resolved by the Annual General Meeting on , became ...
Partnered products 4SC has out-licensed and partnered drug candidates to several national and international pharma and biotech companies.
4SC@optimumcomms.com About 4SC 4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises one drug candidate in clinical development: Kinselby (resminostat).
About 4SC 4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises one drug candidate in clinical development: Kinselby – resminostat.
4SC at a glance Following the negative opinion issued by the European Medicine Agency on Resminostat, efforts to further develop and commercialize the drug has been discontinued. The company no longer has any operating business of its own.
4SC AG provides results for financial year 2024 and outlook for 2025 Planegg-Martinsried, Germany, 28 March 2025 – 4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 2024, presenting all material reporting period developments and providing an outlook for 2025.